ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

This study has been completed.

Sponsored by: Endo Pharmaceuticals
Information provided by: Endo Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00352625
  Purpose

The purpose of this study is to evaluate the effect of a ketoprofen topical patch on the pain associated with tendonitis or bursitis of the shoulder, elbow or knee.


Condition Intervention Phase
Tendonitis
Bursitis
Drug: Ketoprofen Topical Patch 20%
Phase III

MedlinePlus related topics:   Bursitis   

ChemIDplus related topics:   Ketoprofen   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee

Further study details as provided by Endo Pharmaceuticals:

Primary Outcome Measures:
  • Average pain intensity during daily activities

Secondary Outcome Measures:
  • Average pain intensity while at rest
  • Functional disability
  • Use of prn rescue medication
  • Quality of sleep
  • Patient's and physician's global assessments of study medication

Estimated Enrollment:   330
Study Start Date:   June 2006
Study Completion Date:   March 2007
Primary Completion Date:   February 2007 (Final data collection date for primary outcome measure)

Detailed Description:

This randomized, double-blind, placebo-controlled, parallel group study will be conducted in patients with tendonitis or bursitis of the shoulder, elbow or knee. Eligible patients will have tendonitis or bursitis or the shoulder, elbow or knee and will be randomized (in a 1:1 ratio) to receive double-blind treatment with either the KTP or a matching placebo patch to be applied once daily for 21 days. Patients will return to the clinic for assessments on Day 3, Day 7, Day 14 and Day 21; a follow-up assessment will be conducted by telephone on Day 35. At each visit through Day 21, patients will rate their average pain intensity during daily activities and while at rest using the 11-point scale (range 0 to 10), and will rate their functional disability. Patients will also complete an electronic diary in which pain intensity and pain relief ratings will be recorded three times daily. Ratings of the quality of sleep will be recorded in the diary each morning, and the use of study treatment and rescue medication will be recorded in the diary each day. Ibuprofen will be provided as prn rescue medication.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion

  • Males or females 18 years of age or older
  • Diagnosis of tendonitis or bursitis of the shoulder, elbow or knee
  • Meet pain entry criteria
  • Willing to discontinue use of any pain medication not provided by the study

Exclusion:

  • Have tendonitis or bursitis secondary to a systemic inflammatory disease, calcification or requiring surgery
  • Have received corticosteroids in the 30 days preceding screening
  • Have a history or physical examination finding that is incompatible with safe participation in the study
  • Have a history or physical examination finding that is incompatible with study product use
  • Are taking medications or other substances contraindicated due to the nature of the study medication or the potential for drug interactions.
  • Are taking medications that may significantly affect renal function
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00352625

Locations
United States, Texas
PPD    
      Austin, Texas, United States, 78704

Sponsors and Collaborators
Endo Pharmaceuticals

Investigators
Principal Investigator:     PPD     PPD Austin, TX    
  More Information

Study ID Numbers:   EN3269-302
First Received:   June 30, 2006
Last Updated:   August 13, 2008
ClinicalTrials.gov Identifier:   NCT00352625
Health Authority:   United States: Food and Drug Administration

Keywords provided by Endo Pharmaceuticals:
Tendonitis  
Bursitis  
Pain  
Shoulder Pain  
Elbow Pain
Knee Pain
Tendon Injury
Muscle, Bone and Cartilage Disorders

Study placed in the following topic categories:
Ketoprofen
Tendinopathy
Tendon Injuries
Muscular Diseases
Musculoskeletal Diseases
Shoulder Pain
Joint Diseases
Wounds and Injuries
Disorders of Environmental Origin
Pain
Bursitis

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Pharmacologic Actions
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on September 04, 2008




Links to all studies - primarily for crawlers